HC Wainwright Brokers Decrease Earnings Estimates for SRTS

Sensus Healthcare, Inc. (NASDAQ:SRTS - Free Report) - Research analysts at HC Wainwright dropped their Q1 2025 earnings per share (EPS) estimates for shares of Sensus Healthcare in a research note issued to investors on Monday, February 10th. HC Wainwright analyst Y. Chen now expects that the company will post earnings per share of $0.11 for the quarter, down from their prior forecast of $0.14. HC Wainwright has a "Buy" rating and a $12.00 price target on the stock. The consensus estimate for Sensus Healthcare's current full-year earnings is $0.71 per share. HC Wainwright also issued estimates for Sensus Healthcare's Q3 2025 earnings at $0.10 EPS and Q4 2025 earnings at $0.16 EPS.

Several other research firms have also issued reports on SRTS. Lake Street Capital began coverage on Sensus Healthcare in a research report on Friday, January 31st. They issued a "buy" rating and a $18.00 price target on the stock. Maxim Group raised their price target on Sensus Healthcare from $12.00 to $14.00 and gave the stock a "buy" rating in a research report on Friday, November 15th.

Sensus Healthcare Price Performance

Shares of NASDAQ SRTS traded up $0.03 during midday trading on Tuesday, hitting $5.53. The stock had a trading volume of 226,090 shares, compared to its average volume of 427,320. The company's 50-day simple moving average is $7.15 and its 200 day simple moving average is $6.87. The firm has a market cap of $90.55 million, a P/E ratio of 13.85 and a beta of 1.24. Sensus Healthcare has a fifty-two week low of $2.91 and a fifty-two week high of $9.33.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last released its earnings results on Wednesday, February 5th. The company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.01). Sensus Healthcare had a net margin of 15.90% and a return on equity of 12.60%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. bought a new position in Sensus Healthcare during the fourth quarter worth about $27,000. Barclays PLC bought a new position in Sensus Healthcare during the fourth quarter worth about $35,000. Truvestments Capital LLC bought a new position in Sensus Healthcare during the third quarter worth about $32,000. Geode Capital Management LLC lifted its holdings in Sensus Healthcare by 8.5% during the third quarter. Geode Capital Management LLC now owns 146,404 shares of the company's stock worth $849,000 after acquiring an additional 11,525 shares in the last quarter. Finally, XTX Topco Ltd lifted its holdings in Sensus Healthcare by 76.0% during the third quarter. XTX Topco Ltd now owns 31,530 shares of the company's stock worth $183,000 after acquiring an additional 13,619 shares in the last quarter. 25.30% of the stock is currently owned by institutional investors.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.